- Home
- ALLO vs ILLR Comparison
ALLO vs ILLR Comparison
Compare ALLO & ILLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- ILLR
- Stock Information
- Founded
- ALLO 2017
- ILLR 2015
- Country
- ALLO United States
- ILLR United States
- Employees
- ALLO N/A
- ILLR N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- ILLR Investment Managers
- Sector
- ALLO Health Care
- ILLR Finance
- Exchange
- ALLO Nasdaq
- ILLR Nasdaq
- Market Cap
- ALLO 677.5M
- ILLR 644.2M
- IPO Year
- ALLO 2018
- ILLR N/A
- Fundamental
- Price
- ALLO $2.27
- ILLR $3.91
- Analyst Decision
- ALLO Buy
- ILLR
- Analyst Count
- ALLO 12
- ILLR 0
- Target Price
- ALLO $10.06
- ILLR N/A
- AVG Volume (30 Days)
- ALLO 2.6M
- ILLR 1.0M
- Earning Date
- ALLO 11-07-2024
- ILLR 11-25-2024
- Dividend Yield
- ALLO N/A
- ILLR N/A
- EPS Growth
- ALLO N/A
- ILLR N/A
- EPS
- ALLO N/A
- ILLR N/A
- Revenue
- ALLO $43,000.00
- ILLR $46,338,000.00
- Revenue This Year
- ALLO N/A
- ILLR N/A
- Revenue Next Year
- ALLO $5,902.96
- ILLR N/A
- P/E Ratio
- ALLO N/A
- ILLR N/A
- Revenue Growth
- ALLO 26.47
- ILLR N/A
- 52 Week Low
- ALLO $2.01
- ILLR $0.66
- 52 Week High
- ALLO $5.78
- ILLR $8.86
- Technical
- Relative Strength Index (RSI)
- ALLO 36.00
- ILLR N/A
- Support Level
- ALLO $2.95
- ILLR N/A
- Resistance Level
- ALLO $3.36
- ILLR N/A
- Average True Range (ATR)
- ALLO 0.26
- ILLR 0.00
- MACD
- ALLO -0.06
- ILLR 0.00
- Stochastic Oscillator
- ALLO 0.91
- ILLR 0.00
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
About ILLR Triller Group Inc. Common Stock
Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.